Adocia starts Phase I trial of BioChaperone glucagon to treat Type I diabetes

Adocia S.A. (Euronext:ADOC) began a Phase I trial to compare 2 formulations of subcutaneous BioChaperone glucagon to GlucaGen HypoKit from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) in about 27 patients with Type I diabetes. Patients will receive single injections of 50 μg on day 1 and 1 mg on day 2 of all 3 products, separated into 3, two-day dosing visits of 1 agent per visit.

The double-blind, 3-period crossover, German trial is evaluating safety as the primary endpoint and pharmacokinetics as a secondary endpoint. Data from the trial are expected in 4Q17...